David Veesler

David Veesler
Born1981 (age 44–45)
EducationAix-Marseille University
Known forStructural studies of coronavirus spike proteins; pioneering work on coronavirus entry; development of SKYcovione vaccine and sotrovimab antibody; cryo-EM structures of emerging viruses
AwardsNIH Director's Pioneer Award (2020)
Burroughs Wellcome Fund Investigator in the Pathogenesis of Infectious Diseases (2018)
Pew Scholar in Biomedical Sciences (2017)
Scientific career
FieldsStructural biology, Virology, Immunology, Protein design
WorkplacesUniversity of Washington
Christian Cambillau
Websitewww.veeslerlab.com

David Veesler (born 1981, Aix-en-Provence, France) is a French–American structural biologist and Professor of Biochemistry at the University of Washington, where he holds the Hans Neurath Endowed Chair, and an Investigator of the Howard Hughes Medical Institute. His research focuses on the structural and molecular mechanisms of virus entry and immune recognition, as well as on protein design to develop next-generation vaccines and therapeutics.

Veesler pioneered studies of coronavirus entry into cells and elucidated the architecture of coronavirus spike glycoproteins, providing the foundation for the development of COVID-19 vaccines and monoclonal antibody therapeutics. His laboratory carried out key work that led to the authorization of the monoclonal antibody therapy sotrovimab and the approval of the protein nanoparticle vaccine SKYcovione. He has received major honors, including the NIH Director's Pioneer Award and the Burroughs Wellcome Fund Investigator Award in the Pathogenesis of Infectious Diseases.